MARKET

NUVB-WS

NUVB-WS

Nuvation Bio Inc
NYSE
0.3025
-0.0425
-12.32%
Closed 16:00 03/28 EDT
OPEN
0.3030
PREV CLOSE
0.3450
HIGH
0.4088
LOW
0.3000
VOLUME
5.86K
TURNOVER
0
52 WEEK HIGH
0.4450
52 WEEK LOW
0.0325
MARKET CAP
--
P/E (TTM)
-0.8735
1D
5D
1M
3M
1Y
5Y
BUZZ-U.S. STOCKS ON THE MOVE-Nuvation Bio, Seagate, AppFolio
Wall Street's main stock indexes climbed on Tuesday. Dow Jones Industrial Average was up 0.21% at 39,395.24. Most heavyweight growth stocks and chipmakers rose. Nuvation Bio, Seagate, AppFolio among the top percentage gainers.
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Reddit, CONSOL Energy, Nuvation Bio
Dow Jones Industrial Average was up 0.23% on Tuesday. Top three S&P 500 percentage gainers were Seagate Technology, Nuvation Bio and Krispy Kreme. Reddit, Consol Energy and Evercore are among the biggest decliners on the NYSE.
Reuters · 2d ago
BUZZ-Nuvation Bio rises on deal to become commercial organization by 2025
Drug developer Nuvation Bio's shares rise 20% to $2.69. Company agrees to buy cancer therapy developer AnHeart Therapeutics for $270 million. Deal will give co the potential to become a commercial organization by the end of 2025. One of AnHeart's cancer therapies could receive approval as early as 2025.
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, UPS, Dell
U.S. Stock index futures ticked up on Tuesday. Most megacap and chip stocks advanced. Krispy Kreme, UPS, Dell and Newmont rise. Investors readied for more data to assess the Federal Reserve's rate path in a week curtailed by Easter break.
Reuters · 3d ago
Nuvation Bio Inc: Current report
Press release · 4d ago
Weekly Report: what happened at NUVB WS last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at NUVB WS last week (0311-0315)?
Weekly Report · 03/18 09:19
Weekly Report: what happened at NUVB WS last week (0304-0308)?
Weekly Report · 03/11 09:19
More
About NUVB-WS
Nuvation Bio Inc. is a biopharmaceutical company, which is engaged in the development of differentiated and therapeutic candidates to address unmet needs in oncology. Its most advanced clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. It has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its DDC platform is a therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). ADCs are effective treatments in oncology, with around eleven drugs approved by the Food and Drug Administration (FDA).

Webull offers Nuvation Bio Inc stock information, including NYSE: NUVB WS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVB WS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVB-WS stock methods without spending real money on the virtual paper trading platform.